Navigation Links
Asymchem Continues to Maintain a Good Running Posture, Despite Economic Crisis

TIANJIN, China, June 3 /PRNewswire-Asia/ -- Asymchem is pleased to announce its recent award by Pfizer Inc. as the 2008 Top Intermediates CMO Award, and announces the opening of a high potency API and drug product facility, despite the current challenging economic environment. Meanwhile, Dr. Chris Huber joins Asymchem Laboratories Inc. as Director of Chemical Development and is ready to help expand and strengthen Asymchem's already well-established large scale manufacturing services.

    I. Pfizer Global R&D Presents 2008 Top Intermediates CMO Award to Asymchem.

    May 1, 2009 in Groton, Connecticut

Asymchem Laboratories, Inc., a leading research-based contract manufacturer of APIs, intermediates and Drug Products to the pharmaceutical industry with sites in the U.S. and China, is pleased to announce that Pfizer Inc. recently presented Asymchem with the 2008 Top Intermediates CMO Award.

The award was presented at Pfizer's Groton, Connecticut R&D center on May 1, 2009. The award was the first in an annual series to be presented to high-performing chemical intermediates suppliers. "A global network of high-quality chemical intermediate manufacturers is critical to enable Pfizer to create and sustain a competitive advantage," said Laurie Chipperfield, Director of API Strategic Sourcing.

Ed Kobelski, Global VP Supply Chain at Pfizer, presented the award to Dr. Hao Hong, CEO of Asymchem. "The steady growth of Asymchem's business at Pfizer is the result of their successful execution of each project, ability to achieve R&D speed targets, excellent customer service and high technical proficiency," stated Dr. Kobelski.

Pfizer uses a quantitative/qualitative supplier performance assessment process that combines performance data along with feedback from internal R&D and commercial project managers. Supplier excellence is judged on criteria including supplier value, delivery, account support, and compliance.

"I am very excited and honored to receive this award, and sincerely appreciate Pfizer's recognition of Asymchem's dedicated staff," states Dr. Hao Hong, CEO of Asymchem. "By consistently delivering on time and within spec, we help push through projects that are time critical in the clinical arena. Our new Dunhua cGMP commercial production facility coming online later this year will further expand Asymchem's offerings."

II. Asymchem Announces Opening of High Potency API and Drug Product Facility

May 15, 2009 in TEDA Tianjin, China

Asymchem Laboratories, Inc. is pleased to announce the opening if its high potency Active Pharmaceutical Ingredient (API) and Drug Product facility in TEDA Tianjin, China.

This dedicated facility is located at Asymchem's TEDA Tianjin 1 location, and provides state-of-the art containment for production of potent APIs, as well as tablet and capsule manufacturing that incorporates potent ingredients. The new facility allows Asymchem to operate two separate API manufacturing trains of 50 and 100L, as well as additional facilities for smaller-scale research and production and oral dosage form manufacturing.

"We are pleased to expand our capabilities in process research and manufacturing into the potent compound arena, and provide our partners with cost-effective and quality-driven means for undertaking this type of work in China," states Dr Hao Hong, CEO of Asymchem.

Asymchem seeks to be a leader among Chinese-located manufacturing operations not only in facility design but also worker safety, and the Tianjin potent compound site was designed and validated by recognized and accredited experts in the potent compound community. As one of the largest and most respected pharmaceutical manufactures in China, Asymchem is pleased to extend its broad range of API and drug product capabilities to this exciting and rapidly emerging field of drug research and development.

III. Dr. Chris Huber joins Asymchem Laboratories Inc. as Director of Chemical Development

April 23, 2009 in Morrisville, NC

Asymchem Laboratories, Inc. is also pleased to announce the recent addition of Dr. Chris Huber as Director of Chemical Development.

Dr. Huber brings to the table over 15 years experience in the pharmaceutical industry (early and late stage), developing process technology for API manufacturing of small molecules. Prior to Asymchem, Dr. Huber directed early phase projects for API manufacturing at Achaogen Inc. and Arena Pharmaceuticals. Much of his career was spent at Pfizer and legacy companies in process chemistry, with focus on optimization, characterization and validation of Phase 3 processes in preparation for commercial manufacturing of APIs.

As Director of Chemical Development, Dr. Huber will help expand and strengthen Asymchem's pilot scale-up, tech transfers and production efforts into commercial manufacturing. He will report directly to Dr. Jim Gage, VP of Chemical Development.

"I am very pleased to have Dr. Huber on board to help expand and strengthen Asymchem's already well-established large scale manufacturing services," states Dr Hao Hong, CEO of Asymchem. "With his broad experience in the pharmaceutical industry and proven track record of API manufacturing, I am confident that our commercial capabilities will be further strengthened and solidified."

Dr. Huber received his B.S. and M.S. at the Universitat Regensburg, Germany under the supervision of Professors Dr. Henri Brunner, Dr. Jurgen Sauer and Dr. Josef Barthel. He earned his Ph.D. in Organic Chemistry and Catalysis from the Universitat Regensburg, Germany with Professor Dr. Henri Brunner. He did his postdoctoral studies at Purdue University, Indiana under Professor Thomas Bein on the development of supported organometallic catalysts with application in organic synthesis.

About Asymchem

Asymchem Laboratories Inc. is a leading research-based contract manufacturer specialized in the development and compliant manufacturing (Contract Research and Manufacturing Services) of API's and Drug Products serving the pharmaceutical industry. With a 14-year track record, Asymchem is committed to the highest level of quality and excellence in the integrated CMC services arena. For further information, please visit the Asymchem website at .

SOURCE Asymchem Laboratories Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Asymchem Announces Opening of High Potency API and Drug Product Facility
2. Battle Continues Over Vietnam PTSD Numbers
3. U.S. Research Funding Continues to Flatten as U.S. Health Costs Climb - in August 31 Science
4. Therap Services Continues to Hire Experienced Developmental Disability Industry Clinicians for its Customer Support Team
5. Securians Minnesota Life Continues to Climb Group Life Rankings
6. USA TODAY Continues Spirit of the USA Charity Program as Part of Newspapers 25th Anniversary Celebration
7. United States continues to have highest level of health spending
8. LehmanMillet Continues Expansion with Strategic Hires
9. American Cancer Society report finds breast cancer death rate continues to drop
10. CIGNA HealthCare Continues Gains in Health Care Quality
11. Los Angeles Jewish Home Support Group Continues High-Profile Speaker Program With Noted Legal Scholar and Expert Laurie L. Levenson
Post Your Comments:
(Date:6/27/2016)... , ... June 27, 2016 , ... recently awarded ... Eyeglasses . , Millions of individuals in the United States and Canada wear ... a way to both correct vision and make a fashion statement. Even celebrities use ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... PawPaws ... a new product that was developed to enhance the health of felines. The formula ... , The two main herbs in the PawPaws Cat Kidney Support Supplement ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can ... Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey ... cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar ... M.D from the David Geffen School of Medicine at UCLA. He trained in Internal ... complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had ...
(Date:6/24/2016)... Los Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... plastic surgery procedures that most people are unfamiliar with. The article goes on to ... known procedures, but also many of these less common operations such as calf and ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, ... Board will take whatever measures required to build a ... stock which is currently listed on the OTC Markets-pink ... Company Chairman and CEO, "We are seeing an anomaly ... to understand, not only by the Company, but shareholders ...
(Date:6/24/2016)... SAN FRANCISCO, Calif. , June 24, 2016 ... GBT ), a biopharmaceutical company developing novel therapeutics ... significant unmet needs, today announced the closing of ... shares of common stock, at the public offering ... shares in the offering were offered by GBT. ...
(Date:6/24/2016)... , June 24, 2016 The Academy ... of recommendations that would allow biopharmaceutical companies ... with entities that make formulary and coverage decisions, a ... "value" of new medicines. The recommendations address ... not appear on the drug label, a prohibition that ...
Breaking Medicine Technology: